LYMPHANGIOLEIOMYOMATOSIS
Clinical trials for LYMPHANGIOLEIOMYOMATOSIS explained in plain language.
Never miss a new study
Get alerted when new LYMPHANGIOLEIOMYOMATOSIS trials appear
Sign up with your email to follow new studies for LYMPHANGIOLEIOMYOMATOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a leukemia drug help fight rare lung disease? new trial aims to find out
Disease control Recruiting nowThis study tests the long-term safety of imatinib, a drug already approved for leukemia, in women with lymphangioleiomyomatosis (LAM), a rare cystic lung disease. Twenty women aged 18-64 with LAM will receive either imatinib or a placebo for 6 months. The goal is to see if imatin…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Which inhaler works best for rare lung disease? NIH study seeks answers
Symptom relief Recruiting nowThis study tests whether a nebulizer or a standard inhaler (MDI) delivers albuterol better to improve lung function in women with LAM, a rare progressive lung disease. About 100 women with airflow obstruction will stay 3 days at the NIH to receive each method and undergo lung tes…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Symptom relief
Last updated May 01, 2026 16:00 UTC
-
New registry tracks pregnancy risks in rare diseases
Knowledge-focused Recruiting nowThis study collects information from pregnant women with Tuberous Sclerosis Complex (TSC) or Lymphangioleiomyomatosis (LAM) and their babies. Researchers will monitor medication use, side effects, and pregnancy complications to better understand how these conditions affect pregna…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS
Sponsor: David M. Ritter • Aim: Knowledge-focused
Last updated May 04, 2026 16:32 UTC